Enter your keywords

NHS Medicines Optimisation Opportunities Dashboard 2023-24

At the end of July 2023 NHSE published guidance titled “National medicines optimisation opportunities 2023/24”. This guidance describes the 16 national medicines optimisation opportunities for the NHS in 2023/24, and signposts to resources to help with their implementation. It recommends Integrated Care Boards (ICBs) choose at least five medicines optimisation opportunities to focus and deliver […]

Cardiovascular System

This report looks at prescribing trends in primary care for the Cardiovascular System at SICBL and ICB level with particular focus on anticoagulants, antiplatelets and lipid-regulating. Prescribing data is weighted with QOF registers, and also uses HES data to measure prescribing to outcomes. The report also calculates the potential opportunity cost for cardiovascular drugs based […]

Comparison of DOACs for Atrial Fibrillation

Comparison tables are produced for prescribers and medicines management teams. They are designed to assist in prescribing and decision-making within a specific therapeutic area. Several direct oral anticoagulants (DOACs) are licensed for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF). This comparison table allows prescribers and other healthcare […]

Atrial Fibrillation [NICE NG196]: Financial and commissioning impact

In April 2021, NICE published a new guideline NG196 – Atrial fibrillation: diagnosis and management which updates and replaces NICE CG180 (2014). There are a number of new recommendations, which are likely to have both a significant financial impact and potentially affect the way anticoagulation monitoring is managed. This bulletin aims to raise awareness of […]

Cardiovascular outcomes associated with SGLT2 inhibitors (update 2)

The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk. Download the full review below to read […]

Cardiovascular outcomes associated with GLP1 receptor agonists (updated)

The glucagon-like peptide 1 receptor agonists (GLP1RAs) dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population which is also at increased risk of cardiovascular events. Good quality evidence assessed the effect of these drugs on cardiovascular outcomes. Download the full review below […]